Press-release for stocks for icecure medical ltd

Prices are updated after-hours

medical entities : Icecure medical ltd

save search

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| Email alert Add to watchlist
free breast cancer medical trial results

IceCure Medical Reports Full Year 2023 Financial Results
Published: 2024-04-03 (Crawled : 14:00) - biospace.com/
TRUMF | $17.112 -17.59% 1.5K

Health Technology

| -5.58% | O: -8.11% H: 5.66% C: 3.03%
TRUMY | $16.69 0.79% 54K

Manufacturing

| -53.45% | O: 0.52% H: 0.0% C: -3.05%
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| -3.73% | O: -2.24% H: 0.76% C: -4.58%
year medical financial results

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes
Published: 2024-04-02 (Crawled : 17:00) - biospace.com/
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| 0.0% | O: 4.65% H: 0.0% C: -0.74%
fda system

IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
Published: 2024-03-27 (Crawled : 00:00) - biospace.com/
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| 9.32% | O: -0.85% H: 2.56% C: 1.71%
report year medical financial results

IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024
Published: 2024-03-27 (Crawled : 12:30) - prnewswire.com
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| 9.32% | O: -0.85% H: 2.56% C: 1.71%
report year medical financial results

IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy
Published: 2024-03-19 (Crawled : 12:30) - prnewswire.com
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| 6.61% | O: 2.07% H: 0.0% C: 0.0%
free company breast one positive cancer women topline medical alternative results

IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference
Published: 2024-03-07 (Crawled : 15:00) - biospace.com/
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| Email alert Add to watchlist
conference services medical

IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024
Published: 2024-03-04 (Crawled : 15:00) - biospace.com/
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| Email alert Add to watchlist
prosense treatment alternative study

IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan
Published: 2024-02-15 (Crawled : 14:00) - biospace.com/
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| Email alert Add to watchlist
prosense japan medical

IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class
Published: 2024-01-29 (Crawled : 15:00) - biospace.com/
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| Email alert Add to watchlist
first breast meeting

IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
Published: 2024-01-12 (Crawled : 21:00) - globenewswire.com
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| Email alert Add to watchlist
nasdaq medical

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results
Published: 2024-01-10 (Crawled : 14:00) - biospace.com/
TRUMF | $17.112 -17.59% 1.5K

Health Technology

| -48.26% | O: 2.43% H: 3.23% C: 0.01%
TRUMY | $16.69 0.79% 54K

Manufacturing

| -50.27% | O: 2.4% H: 1.38% C: 0.8%
sales ceo medical results

New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response
Published: 2024-01-03 (Crawled : 13:00) - prnewswire.com
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| 11.21% | O: 3.88% H: 0.0% C: 0.0%
prosense cell response study

IceCure's ProSense® Deepens Regulatory Approval in India
Published: 2023-11-29 (Crawled : 19:00) - biospace.com/
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| Email alert Add to watchlist
prosense approval india

IceCure Medical Files Appeal with U.S. FDA Requesting a Review of its De Novo Classification for ProSense® in Early-Stage Breast Cancer
Published: 2023-11-15 (Crawled : 12:30) - prnewswire.com
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| Email alert Add to watchlist
prosense fda breast review cancer medical

IceCure Medical to Report Third Quarter 2023 Financial & Operational Results on November 15, 2023
Published: 2023-11-08 (Crawled : 14:00) - biospace.com/
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| Email alert Add to watchlist
report medical financial results

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
Published: 2023-11-03 (Crawled : 20:00) - prnewswire.com
ICCM | $1.24 -3.88% -4.03% 110K

Manufacturing

| Email alert Add to watchlist
nasdaq medical